Open AccessProspects for using a perindopril/amlodipine combination in patients with hypertension and/or coronary artery disease and COVID-19: focus on the endothelium
Author(s) -
O. A. Polyakova,
А. И. Кочетков,
О. Д. Остроумова
Publication year - 2022
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2022-4888
Subject(s) - medicine , perindopril , endothelial dysfunction , cardiology , coronary artery disease , amlodipine , disease , covid-19 , endothelium , intensive care medicine , blood pressure , infectious disease (medical specialty)
The outbreak of the coronavirus disease 2019 (COVID-19) pandemic is an ongoing public health emergency that has caused unprecedented morbidity and mortality. COVID-19 is a disease caused by severe acute respiratory syndromerelated coronavirus 2 (SARS-CoV-2), which affects not only the lungs but also the cardiovascular system. A strong theoretical justification for the multisystem effect of COVID-19 is the close relationship between it and endothelial dysfunction, which, according to expert consensus, is crucial for the pathogenesis and severity of the disease. Endothelial dysfunction is considered as the main pathophysiological process in the severe and/or prolonged course of COVID-19, and is probably the common denominator of many clinical aspects of severe COVID-19. This review presents scientific data on the effect of perindopril and amlodipine in patients with hypertension and/or coronary heart disease and COVID-19 on endothelial function.